High dose administration of DREADD agonist JHU37160 produces increases in anxiety-like behavior in male rats

Behav Brain Res. 2023 Aug 24:452:114553. doi: 10.1016/j.bbr.2023.114553. Epub 2023 Jun 21.

Abstract

Designer receptors exclusively activated by designer drugs (DREADDs) are a promising tool for analyzing neural circuitry, and improved DREADD-selective ligands continue to be developed. Relative to clozapine-N-oxide (CNO), JHU37160 is a selective DREADD agonist recently shown to exhibit higher blood brain barrier penetrance and DREADD selectivity in vivo; however, relatively few studies have characterized the behavioral effects of systemic JHU37160 administration in animals. Here, we report a dose-dependent anxiogenic effect of systemic JHU37160 in male Wistar and Long-Evans rats, regardless of DREADD expression, with no impact on locomotor behavior. These results suggest that high dose (1 mg/kg) JHU37160 should be avoided when performing chemogenetic experiments designed to evaluate circuit manipulation on anxiety-like behavior in rats.

Keywords: Anxiety-like behavior; DREADDs; JHU37160; Rat.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Blood-Brain Barrier* / metabolism
  • Clozapine* / pharmacology
  • Male
  • Rats
  • Rats, Long-Evans
  • Rats, Wistar

Substances

  • JHU37160
  • Clozapine